Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 107, Issue 5, Pages 536-543Publisher
WILEY-BLACKWELL
DOI: 10.1002/jso.23282
Keywords
CAI; CAII; CAIX; p53; acetazolamide; pancreatic cancer; prognostic biomarker
Funding
- Scientific Research from Science and Technology Committee of Liaoning Province, China [2010225032]
- Shenyang Science and Technology Bureau, China [F12-193-9-21]
- center of experimental medicine and laboratory technology
- central laboratory of China Medical University
Ask authors/readers for more resources
Background and Objectives Altered expression of carbonic anhydrase (CA)I and II associated with human carcinogenesis. But there was no definite study investigating their expression for clinical significance in pancreatic cancer and effect of the CA inhibitor acetazolamide (AZ) on regulation biological behavior of pancreatic cancer cells. Methods Immunohistochemistry, immunofluorescence, immunoblot, and qRT-PCR were used to detect CAI, II, and p53 expression. Tumor cell viability, apoptosis, and invasion assays were used to investigate the effect of AZ on pancreatic cancer cells. Results Expression of CAI and p53 was increased in pancreatic cancer than that in paired non-cancerous tissues (P=0.021; P=0.007), whereas CAII was down-regulated in pancreatic cancer (P=0.001). CAI overexpression was associated with tumor differentiation and negatively with vascular invasion (P=0.015 and P=0.018, respectively), while overexpression of CAII was associated with tumor differentiation (P=0.017) and a better prognosis of pancreatic cancer patients (P=0.017), and was an independent prognostic indicator (P=0.011). p53 overexpression was related with lymph node metastasis (P=0.032) and TNM stage (P=0.016). Treatment with AZ inhibited tumor cell validity, invasion, and induced apoptosis in some of six pancreatic cancer cells. Conclusion This study suggests the clinical significance of CAI, CAII and p53 expression in pancreatic cancer and provides evidence for AZ as a potential target for controlling pancreatic cancer. J. Surg. Oncol. 2013;107:536543. (c) 2012 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available